Efficacy study of metronomic chemotherapy in triple negative metastatic breast cancer.

e12569Background: We evaluated the effects of metronomic chemo (MC) on survival outcomes in refractory MBC population. Methods: 28 subjects with treatment refractory (21) and treatment naive (7) MBC were included in an open label single arm efficacy study of MC. Patients were given a chemotherapy regimen of Tab. Cyclophosphamide 50mg once daily and Tab. Methotrexate 2.5mg twice in a week for 3 months or until the progression of their disease whichever was earlier. Patients were assessed for treatment response using RECIST Criteria (v 1.1) and duration of PFS and OS. Monitoring of S. VEGF and TSP levels were done to correlate the RR. Data were analysed using chi square test for proportions and Kaplan Meir Survival analysis. Results: The mean age of the study population was 51.5 ±14.2 years. The mean duration of MC was 123.89 ±97.6 days. Overall 71.4% had PD and 28.6% had SD. 55.6% with treatment naive MBC had SD compared to 15.8% of treatment refractory MBC (χ2 = 4.7, p = 0.03). There was a significant imp...